Cargando…
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963147/ https://www.ncbi.nlm.nih.gov/pubmed/35348779 http://dx.doi.org/10.1093/oncolo/oyac015 |
| Sumario: | In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies. |
|---|